TechnoPhage is an innovative biopharmaceutical company engaged in the R&D of new molecules - chemical and biological - in diverse therapeutic areas, such as infection, inflammation & immunology, neurology and metabolic disorders. TechnoPhage's strategy is based on developing new therapeutics in early phases of R&D, with a view to then enters into collaboration deals for pre-clinical and/or clinical development.
TechnoPhage is developing proprietary drug discovery products in either discovery, pre-clinical or clinical stage. The company has several patents in place and successfully developed one of its products into clinical Phase I. TechnoPhage is focused on increasing its portfolio of proprietary technologies and deriving products. This is achieved through an active R&D program and collaboration agreements with national and international pharmaceutical companies, research centers and universities across the US, Europe and Asia.
The company's laboratories are located at the iMM in Lisbon, under a scientific collaboration protocol signed by both entities. Close proximity to the renowned Santa Maria Hospital and the iMM help facilitate the creation of powerful multidisciplinary teams, essential to the process of translational medicine. Furthermore this proximity helps to facilitate access to the necessary equipment and talent required to develop full product solutions, including direct collaboration with leading experts from the clinical fields covering the therapeutic products under development.